PG(16:0/18:3(9Z,12Z,15Z)) (BioCAD00000024154)

all tissues

Metabolite Card

Formula: C40H73O10P (744.4941)
SMILES: [H][C@](O)(CO)COP(O)(=O)OC[C@@]([H])(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC\C=C/C\C=C/C\C=C/CC

Synonyms [en]

PG(16:0/18:3(9Z,12Z,15Z)); PG(34:3); GPG(16:0/18:3); GPG(16:0/18:3W3); PG(16:0/18:3); Phosphatidylglycerol(16:0/18:3)

Reviewed

Last reviewed on 2024-06-28.

Cite this Page

PG(16:0/18:3(9Z,12Z,15Z)). 数据之源,洞见之始. SMRUCC genomics institute, a synthetic life researcher from China. https://biocad_registry.innovation.ac.cn/s/(-)-arctiin (retrieved 2026-01-03) (CAD Registry RN: BioCAD00000024154). Licensed under the Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0).

Note

PG(16:0/18:3(9Z,12Z,15Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(16:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of a-linolenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phosphatidylglycerol is present at a level of 1-2% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1'-sn-glycerol 3'-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate.

Entity Information

DBLinks

Other DBLinks
  • PubChem: 52927236
  • HMDB: HMDB0010577
  • HMDB: HMDB10577
  • LipidMaps: LMGP04010973
  • Metlin: METLIN_61853

Class / Ontology

Metabolic Network
ID EC Number Name
View More
Organism Source

Taxonomy Source

Pathway Synthetic

pathway id name
PathBank:SMP0081175 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
PathBank:SMP0081179 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/22:0)
PathBank:SMP0081183 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:0/20:1(13Z))
PathBank:SMP0081187 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:1(11Z)/20:1(13Z))
PathBank:SMP0081191 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:1(13Z)/22:0)
PathBank:SMP0081195 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/22:1(13Z)/22:1(13Z))
PathBank:SMP0083834 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))
PathBank:SMP0083838 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
PathBank:SMP0083842 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:0/20:3(5Z,8Z,11Z))
PathBank:SMP0083846 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:0/20:5(5Z,8Z,11Z,14Z,17Z))
PathBank:SMP0083850 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:3(5Z,8Z,11Z)/20:4(8Z,11Z,14Z,17Z))
PathBank:SMP0083854 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:3(8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
PathBank:SMP0083858 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))
PathBank:SMP0098598 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
PathBank:SMP0098602 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:0/20:0)
PathBank:SMP0098606 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:0/22:0)
PathBank:SMP0098610 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:1(11Z)/20:4(8Z,11Z,14Z,17Z))
PathBank:SMP0098614 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))
PathBank:SMP0098618 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/20:4(8Z,11Z,14Z,17Z)/22:0)
PathBank:SMP0098622 Cardiolipin Biosynthesis CL(16:0/18:3(9Z,12Z,15Z)/22:1(13Z)/22:1(13Z))
View All Pathways